Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.5098
+0.00981.96%
Post-market: 0.51000.0002+0.04%19:59 EDT
Volume:2.67M
Turnover:1.36M
Market Cap:184.29M
PE:-0.81
High:0.5262
Open:0.5001
Low:0.4980
Close:0.5000
Loading ...

Lexicon Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $4 From $5

THOMSON REUTERS
·
14 Nov 2024

Lexicon Pharmaceuticals (LXRX) Gets a Buy from Piper Sandler

TIPRANKS
·
13 Nov 2024

Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Nov 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

GuruFocus.com
·
13 Nov 2024

Lexicon Pharmaceuticals Inc reports results for the quarter - Earnings Summary

Reuters
·
13 Nov 2024

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
13 Nov 2024

Lexicon: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Lexicon Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $1.800M Miss $2.929M Estimate

Benzinga
·
13 Nov 2024

Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings

TIPRANKS
·
13 Nov 2024

Lexicon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

GlobeNewswire
·
06 Nov 2024

Lexicon announces JASN publishes sotagliflozin data

TIPRANKS
·
06 Nov 2024

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire
·
06 Nov 2024

Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Nov 2024

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

GlobeNewswire
·
05 Nov 2024

Lexicon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
04 Nov 2024

BRIEF-Lexicon To Present Preclinical In Vivo Efficacy Data Demonstrating Ability Of New Investigational Compound To Enhance And Maintain Semaglutide-Promoted Weight Loss

Reuters
·
04 Nov 2024

Lexicon to Present Preclinical in Vivo Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

THOMSON REUTERS
·
04 Nov 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

GlobeNewswire
·
04 Nov 2024

Top Midday Decliners

MT Newswires Live
·
02 Nov 2024